Glycan-related gene expression signatures in breast cancer subtypes; relation to survival

Molecular Oncology

Volumn 9, Issue 4, 2015, Pages 861-876

  Potapenko, Ivan O ^a,b   Lüders, Torben ^c   Russnes, Hege G ^a,b   Helland, Åslaug ^a,b   Sørlie, Therese ^a,b   Kristensen, Vessela N ^a,b,c   Nord, Silje ^a,b   Lingjærde, OleC ^d   Børresen Dale, Anne Lise ^a,b   Haakensen, Vilde D ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Breast cancer; Carcinogenesis; Gene expression profiling; Glycosphingolipids; Glycosylation; Survival

Indexed keywords

GLYCAN; GLYCOSAMINOGLYCAN; POLYSACCHARIDE;

ARTICLE; B3GNT5 GENE; B4GALNT4 GENE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA IN SITU; CHSY1 GENE; CLEC3B GENE; CLGN GENE; CONTROLLED STUDY; DOWN REGULATION; EDEM3 GENE; FEMALE; FUCA1 GENE; GALNT3 GENE; GALNT6 GENE; GENE; GENE EXPRESSION; GLYCOSYLATION; HUMAN; HUMAN TISSUE; ICAM2 GENE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PECAM1 GENE; PRIORITY JOURNAL; SLC35B1 GENE; SULFATION; BREAST TUMOR; CLASSIFICATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SURVIVAL;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; HUMANS; POLYSACCHARIDES; SURVIVAL ANALYSIS;

EID: 84926409297     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.12.013     Document Type: Article

References (57)

1. Ang L.C., Zhang Y., Cao L., Yang B.L., Young B., Kiani C., Lee V., Allan K., Yang B.B. Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J.Neuropathol. Exp. Neurol. 1999, 58:597-605.
2. Benito M., Parker J., Du Q., Wu J., Xiang D., Perou C.M., Marron J.S. Adjustment of systematic microarray data biases. Bioinformatics 2004, 20:105-114.
3. Bülow H.E., Hobert O. Differential sulfations and epimerization define heparan sulfate specificity in nervous system development. Neuron 2004, 41:723-736.
4. Buskas T., Thompson P., Boons G.-J. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. Chem. Commun. (Camb) 2009, 5335-5349.
5. Cazet A., Julien S., Bobowski M., Krzewinski-Recchi M.-A., Harduin-Lepers A., Groux-Degroote S., Delannoy P. Consequences of the expression of sialylated antigens in breast cancer. Carbohydr. Res. 2010, 345:1377-1383.
6. Cichon M.A., Degnim A.C., Visscher D.W., Radisky D.C. Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J.Mammary Gland Biol. Neoplasia 2010, 15:389-397.
7. Curtis C., Shah S.P., Chin S.-F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., Gräf S., Ha G., Haffari G., Bashashati A., Russell R., McKinney S., Langerød A., Green A., Provenzano E., Wishart G., Pinder S., Watson P., Markowetz F., Murphy L., Ellis I., Purushotham A., Børresen-Dale A.-L., Brenton J.D., Tavaré S., Caldas C., Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
8. Deepa S.S., Umehara Y., Higashiyama S., Itoh N., Sugahara K. Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues. J.Biol. Chem. 2002, 277:43707-43716.
9. Dennis J.W., Granovsky M., Warren C.E. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1999, 1473:21-34.
10. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 1998, 95:14863-14868.
11. Enerly E., Steinfeld I., Kleivi K., Leivonen S.-K., Aure M.R., Russnes H.G., Rønneberg J.A., Johnsen H., Navon R., Rødland E., Mäkelä R., Naume B., Perälä M., Kallioniemi O., Kristensen V.N., Yakhini Z., Børresen-Dale A.-L. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 2011, 6:e16915.
12. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S.A., Nobel A.B., van't Veer L.J., Perou C.M. Concordance among gene-expression-based predictors for breast cancer. N.Engl. J. Med. 2006, 355:560-569.
13. Fleischer T., Frigessi A., Johnson K.C., Edvardsen H., Touleimat N., Klajic J., Riis M., Haakensen V.D., Wärnberg F., Naume B., Helland Å., Børresen-Dale A.-L., Tost J., Christensen B.C., Kristensen V.N. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol. 2014, 15:435.
14. Gilewski T.A., Ragupathi G., Dickler M., Powell S., Bhuta S., Panageas K., Koganty R.R., Chin-Eng J., Hudis C., Norton L., Houghton A.N., Livingston P.O. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin. Cancer Res. 2007, 13:2977-2985.
15. Ginestier C., Cervera N., Finetti P., Esteyries S., Esterni B., Adélaïde J., Xerri L., Viens P., Jacquemier J., Charafe-Jauffret E., Chaffanet M., Birnbaum D., Bertucci F. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin. Cancer Res. 2006, 12:4533-4544.
16. Gu J., Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj. J. 2004, 21:9-15.
17. Haakensen V.D., Lingjaerde O.C., Lüders T., Riis M., Prat A., Troester M.A., Holmen M.M., Frantzen J.O., Romundstad L., Navjord D., Bukholm I.K., Johannesen T.B., Perou C.M., Ursin G., Kristensen V.N., Børresen-Dale A.-L., Helland A. Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Med. Genomics 2011, 4:77.
18. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
19. Holm K., Hegardt C., Staaf J., Vallon-Christersson J., Jönsson G., Olsson H., Borg A., Ringnér M. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010, 12:R36.
20. Hsu P.-Y., Hsu H.-K., Lan X., Juan L., Yan P.S., Labanowska J., Heerema N., Hsiao T.-H., Chiu Y.-C., Chen Y., Liu Y., Li L., Li R., Thompson I.M., Nephew K.P., Sharp Z.D., Kirma N.B., Jin V.X., Huang T.H.-M. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell 2013, 24:197-212.
21. Julien S., Ivetic A., Grigoriadis A., QiZe D., Burford B., Sproviero D., Picco G., Gillett C., Papp S.L., Schaffer L., Tutt A., Taylor-Papadimitriou J., Pinder S.E., Burchell J.M. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res. 2011, 71:7683-7693.
22. KEGG Glycan Database. (accessed 14.05.14). http://www.genome.jp/kegg/glycan/.
23. Langerød A., Zhao H., Borgan Ø., Nesland J.M., Bukholm I.R.K., Ikdahl T., Kåresen R., Børresen-Dale A.-L., Jeffrey S.S. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007, 9:R30.
24. Lau K.S., Dennis J.W. N-Glycans in cancer progression. Glycobiology 2008, 18:750-760.
25. Lu P., Takai K., Weaver V.M., Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 2011, 3.
26. Milde-Langosch K., Karn T., Schmidt M., zu Eulenburg C., Oliveira-Ferrer L., Wirtz R.M., Schumacher U., Witzel I., Schütze D., Müller V. Prognostic relevance of glycosylation-associated genes in breast cancer. Breast Cancer Res. Treat. 2014, 145:295-305.
27. Miles D., Roché H., Martin M., Perren T.J., Cameron D.A., Glaspy J., Dodwell D., Parker J., Mayordomo J., Tres A., Murray J.L., Ibrahim N.K. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011, 16:1092-1100.
28. Muggerud A.A., Hallett M., Johnsen H., Kleivi K., Zhou W., Tahmasebpoor S., Amini R.-M., Botling J., Børresen-Dale A.-L., Sørlie T., Wärnberg F. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol. Oncol. 2010, 4:357-368.
29. Myhre S., Mohammed H., Tramm T., Alsner J., Finak G., Park M., Overgaard J., Børresen-Dale A.-L., Frigessi A., Sørlie T. In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome. PLoS One 2010, 5:e14002.
30. Narayan G., Murty V.V. Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. Future Oncol. 2010, 6:1643-1652.
31. Naume B., Zhao X., Synnestvedt M., Borgen E., Russnes H.G., Lingjaerde O.C., Strømberg M., Wiedswang G., Kvalheim G., Kåresen R., Nesland J.M., Børresen-Dale A.-L., Sørlie T. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol. Oncol. 2007, 1:160-171.
32. Nielsen H.M., Overgaard M., Grau C., Jensen A.R., Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J.Clin. Oncol. 2006, 24:2268-2275.
33. Padró M., Cobler L., Garrido M., de Bolós C. Down-regulation of FUT3 and FUT5 by shRNA alters Lewis antigens expression and reduces the adhesion capacities of gastric cancer cells. Biochim. Biophys. Acta 2011, 1810:1141-1149.
34. Parker J., Prat A., Perou C.M. UNC UMD Supplement: How to Perform Intrinsic Subtype Classifications 9-6-10 2010, (accessed 13.09.14). https://genome.unc.edu/pubsup/breastGEO/Guide%20to%20Intrinsic%20Subtyping%209-6-10.pdf.
35. Parker J.S., Mullins M., Cheang M.C.U., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., Quackenbush J.F., Stijleman I.J., Palazzo J., Marron J.S., Nobel A.B., Mardis E., Nielsen T.O., Ellis M.J., Perou C.M., Bernard P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J.Clin. Oncol. 2009, 27:1160-1167.
36. Partridge E.A., Le Roy C., Di Guglielmo G.M., Pawling J., Cheung P., Granovsky M., Nabi I.R., Wrana J.L., Dennis J.W. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 2004, 306:120-124.
37. Perou C.M., Børresen-Dale A.-L. Systems biology and genomics of breast cancer. Cold Spring Harb. Perspect. Biol. 2011, 3.
38. Potapenko I.O., Haakensen V.D., Lüders T., Helland A., Bukholm I., Sørlie T., Kristensen V.N., Lingjaerde O.C., Børresen-Dale A.-L. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol. Oncol. 2010, 4:98-118.
39. Rabu C., McIntosh R., Jurasova Z., Durrant L. Glycans as targets for therapeutic antitumor antibodies. Future Oncol. 2012, 8:943-960.
40. Rønneberg J.A., Fleischer T., Solvang H.K., Nordgard S.H., Edvardsen H., Potapenko I., Nebdal D., Daviaud C., Gut I., Bukholm I., Naume B., Børresen-Dale A.-L., Tost J., Kristensen V. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol. Oncol. 2011, 5:61-76.
41. Russnes H.G., Vollan H.K.M., Lingjaerde O.C., Krasnitz A., Lundin P., Naume B., Sørlie T., Borgen E., Rye I.H., Langerød A., Chin S.-F., Teschendorff A.E., Stephens P.J., Månér S., Schlichting E., Baumbusch L.O., Kåresen R., Stratton M.P., Wigler M., Caldas C., Zetterberg A., Hicks J., Børresen-Dale A.-L. Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci. Transl. Med. 2010, 2. 38ra47.
42. Silwal-Pandit L., Vollan H.K.M., Chin S.-F., Rueda O.M., McKinney S., Osako T., Quigley D.A., Kristensen V.N., Aparicio S., Børresen-Dale A.-L., Caldas C., Langerød A. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin. Cancer Res. 2014, 20:3569-3580.
43. Slovin S.F., Keding S.J., Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol. 2005, 83:418-428.
44. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lønning P.E., Børresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
45. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lønning P.E., Brown P.O., Børresen-Dale A.-L., Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100:8418-8423.
46. Stanford Microarray Database. (accessed 14.05.14). http://smd.princeton.edu/.
47. Sugahara K., Mikami T., Uyama T., Mizuguchi S., Nomura K., Kitagawa H. Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate. Curr. Opin. Struct. Biol. 2003, 13:612-620.
48. Tarp M.A., Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim. Biophys. Acta 2008, 1780:546-563.
49. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 2001, 98:5116-5121.
50. WebGestalt. (accessed 23.06.4). http://bioinfo.vanderbilt.edu/webgestalt/.
51. Wei Y., Liu D., Ge Y., Zhou F., Xu J., Chen H., Yun X., Gu J., Jiang J. Down-regulation of beta1,4GalT V at protein level contributes to arsenic trioxide-induced glioma cell apoptosis. Cancer Lett. 2008, 267:96-105.
52. Welch H.G., Black W.C. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find?. Ann. Intern. Med. 1997, 127:1023-1028.
53. Wiedswang G., Borgen E., Kåresen R., Kvalheim G., Nesland J.M., Qvist H., Schlichting E., Sauer T., Janbu J., Harbitz T., Naume B. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J.Clin. Oncol. 2003, 21:3469-3478.
54. Yi W., Clark P.M., Mason D.E., Keenan M.C., Hill C., Goddard W.A., Peters E.C., Driggers E.M., Hsieh-Wilson L.C. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 2012, 337:975-980.
55. Zhao Y., Nakagawa T., Itoh S., Inamori K., Isaji T., Kariya Y., Kondo A., Miyoshi E., Miyazaki K., Kawasaki N., Taniguchi N., Gu J. N-acetylglucosaminyltransferase III antagonizes the effect of N-acetylglucosaminyltransferase V on alpha3beta1 integrin-mediated cell migration. J.Biol. Chem. 2006, 281:32122-32130.
56. Zhao Y., Sato Y., Isaji T., Fukuda T., Matsumoto A., Miyoshi E., Gu J., Taniguchi N. Branched N-glycans regulate the biological functions of integrins and cadherins. FEBS J. 2008, 275:1939-1948.
57. Zhou H., Ma H., Wei W., Ji D., Song X., Sun J., Zhang J., Jia L. B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1. Cell Death Dis. 2013, 4:e654.